Clinical characteristics | Group A (n = 36) | Group B (n = 24) | |
---|---|---|---|
Age, years* | 74 (70–79) | 71 (64–79) | 0.149 |
Gender, male/female | 8/28 | 6/18 | 0.999 |
Etiology (HCV/HBV/Alcohol/Unknown) | 16/8/8/4 | 9/5/6/4 | 0.912 |
Child-Pugh classification (A/B) | 31/5 | 19/5 | 0.569 |
BCLC stage(0/A/B) | 11/20/5 | 5/17/2 | 0.545 |
Size of tumor, mm* | 14.5 (12–21.3) | 15.5 (11–22) | 0.757 |
Thickness of corona enhancement(≤ 2mm/>2mm) | 17/19 | 10/14 | 0.793 |
AFP, ng/ml* | 4.9 (2.6–10.6) | 5.9 (2.7–14.1) | 0.419 |
DCP, mAU/mL* | 26.4 (17.0–49.2) | 48.8 (25.3–153.9) | 0.021 |
Usage of miriplatin, mg* | 28 (20–38.5) | 30 (22.4–51.5) | 0.310 |
Factor | Univariate analysis |
Multivariate analysis |
||
---|---|---|---|---|
Odds ratio (95% CI) | Odds ratio (95% CI) | |||
Size of tumor (< 20 |
0.67 (0.20–2.32) | 0.577 | ||
AFP (< 10 |
0.45 (0.13–1.61) | 0.242 | ||
DCP (< 40 |
0.59 (0.18–1.92) | 0.417 | ||
Usage of miriplatin (< 30 |
0.70 (0.17–1.89) | 0.420 | ||
Thickness of corona enhancement (≤ 2mm/ > 2mm) | 0.97 (0.30–3.20) | 0.999 | ||
Degree of iodized oil accumulation (Group A |
0.045 (0.0080–0.20) | < 0.001 | 0.042 (0.010–0.17) | < 0.001 |